Compare Davita Inc (DVA) vs KraneShares Electric Vehicles and Future Mobility (KARS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Davita Inc vs KraneShares Electric Vehicles and Future Mobility — how do they compare? Davita Inc trades at $178.35 (market cap $11.38B), while KraneShares Electric Vehicles and Future Mobility trades at $30.99. The key difference: Davita Inc is trading nearer its 52-week high, KraneShares Electric Vehicles and Future Mobility nearer its low. Which is the better fit depends on your goals.
| DVA | KARS | |
|---|---|---|
Market Cap | $11.38B | — |
Sector | Health | Sector/Thematic |
52-Week High | $240.96 | $38.01 |
52-Week Low | $103.87 | $25.59 |
Enterprise Value | $24.10B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $181.72, down 1.07% on the day, with technical indicators showing a mixed but overall bullish signal. The stock has consistently beaten earnings expectations in recent quarters, with Q2 2026 EPS of $4.02 surpassing estimates. Revenue growth is steady, reaching $13.64B in 2025, though net income margin has fluctuated. Analyst sentiment is cautiously optimistic with a consensus price target of $232.25, representing significant upside potential from current levels.
The outlook for DVA is positive, driven by strong volume growth and strategic execution, but faces risks from reimbursement pressures and a high debt load. Investment opportunity lies in the valuation discount to analyst targets and consistent earnings beats, while key risks include payer mix challenges and macroeconomic factors affecting healthcare spending.
KARS trades at $30.95, down 0.55% today, with a bullish technical signal driven by moving averages and oscillators, though the RSI_6 at 85.22 suggests overbought conditions. Support lies near $30, resistance at $31. Recent news highlights strong global EV sales growth, particularly in Europe and China, driven by high fuel prices and policy support, though U.S. adoption lags.
The outlook for KARS is supported by accelerating EV adoption globally, but risks include U.S. market hesitation, competitive pressures from Chinese automakers, and potential volatility from geopolitical events. Analyst sentiment is mixed, with technical indicators bullish but valuation metrics unavailable, requiring close monitoring of upcoming financial results for clarity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →About KraneShares Electric Vehicles and Future Mobility
KARS invests in the global electric vehicle ecosystem and future mobility. It tracks the Bloomberg Electric Vehicles Index, providing exposure to EV manufacturers, battery technology, and lithium miners like Tesla, BYD, and Albemarle.
Read more on KARS →
